Shares of Novartis NVS decreased 3.8% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 1.52% over the past year to $1.34, which missed the estimate of $1.36.
Revenue of $12,770,000,000 rose by 2.96% year over year, which missed the estimate of $12,870,000,000.
Guidance
Novartis hasn't issued any earnings guidance for the time being.
Novartis hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Jan 26, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/g655yyy5
Price Action
52-week high: $99.84
Company's 52-week low was at $69.18
Price action over last quarter: Up 20.93%
Company Profile
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.